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ABSTRACT  
The interaction of IFN-β with its receptor 
IFNAR1 is vital for host-protective anti-viral and 
anti-proliferative responses, but signaling via this 
interaction can be detrimental if dysregulated. 
While it is established that IFNAR1 is an essential 
component of the IFNAR signaling complex, the 
key residues underpinning the IFN-β-IFNAR1 
interaction are unknown. Guided by the crystal 
structure of the IFN-β-IFNAR1 complex, we used 
truncation variants and site directed mutagenesis to 
investigate domains and residues enabling 
complexation of IFN-β to IFNAR1. We have 
identified an interface on IFNAR1-subdomain 
(SD)-3 that is differentially utilized by IFN-β and 
IFN-α for signal transduction. We used surface 
plasmon resonance and cell-based assays to 
investigate this important IFN-β binding interface 
which is centered on IFNAR1 residues Y240 and 
Y274 binding the C-terminal and N-terminal of B 
and C helices of IFN-β, respectively. Using 
IFNAR1 and IFN-β variants, we show that this 
interface contributes significantly to the affinity of 
IFN-β for IFNAR1, its ability to activate STAT1, 
the expression of interferon stimulated genes and 
ultimately to the anti-viral and anti-proliferative 
properties of IFN-β. These results identify a key 
interface created by IFNAR1 residues Y240 and Y274 
interacting with IFN-β residues F63, L64, E77, T78, 
V81, R82 that underlie IFN-β-IFNAR1 mediated 
signaling and biological processes. 
 
 
 
The type I IFNs, including 14 IFN-α, and 
lone IFN-β, IFN-ε and IFN-ω, have critical roles in 
response to viral and bacterial infections, and 
cancers (1,2). They are also applied clinically for 
the treatment of hepatitis virus B and C (1), cancers 
including melanoma (3), and multiple sclerosis (4). 
Although they show clinical efficacy, their use is 
restricted by dose-limiting toxicities, including 
leukopenia, nausea, fatigue, neurological disorders 
(3), and localized cutaneous effects (5). All type I 
IFNs engage their cognate receptors, IFNAR1 and 
IFNAR2, to activate the canonical JAK-STAT 
signaling pathway, but ligand engagement can also 
activate alternative signaling pathways (6). Despite 
sharing these receptor components, there are IFN 
subtype-specific elements to signaling: compared 
to IFN-α, IFN-β has specific roles in osteo-
clastogenesis (7), control of chronic viral infection 
(8), the potent induction of apoptotic pathways 
required for control of tumor cell growth and the 
development of B cells and myelopoiesis (9). 
Structural insight into the IFN-IFNAR 
interactions has been gleaned from the crystal 
structures of a human IFN-α2 variant and human 
IFN-ω in complex with both IFNAR1 and IFNAR2 
(10). Furthermore, specific insight into the mode of 
IFN-β-mediated activation of IFNAR1 was 
obtained from the crystal structure of the murine 
IFN-β-IFNAR1 complex (11). Comparison of these 
structures and evidence form the literature (12) 
suggests that the minimal ligand binding domains 
for human and mouse IFNAR1 are similar, and sit 
broadly across the three membrane distal SDs 
(SD1-3) of the receptor with limited involvement 
of the membrane proximal subdomain, SD4 (Fig. 
1A). It has also been shown that key residues 
discriminate between ligands and that there is 
potential for ligand-specific interaction interfaces 
(10,11). However experimental validation of these 
predictions is lacking. 
The current study investigates the ligand-
receptor subdomains and residues that contribute to 
the formation of a stable complex between IFN-β 
and the extracellular domain (ECD) of IFNAR1. 
Using subdomain truncation variants of IFNAR1-
ECD we initially show that IFNAR1-SD3 is vital to 
the formation of a stable IFN-β-IFNAR1 complex. 
We next interrogated the crystal structure of the 
IFN-β-IFNAR1 complex, focusing on key residues 
on IFNAR1-SD3 and residues to which they 
interact on IFN-β. Our data reveals that a key 
interaction interface exists between two tyrosine 
residues on IFNAR1-SD3 and a small number of 
residues on IFN-β helices B and C. Using site 
directed mutagenesis we demonstrate that this 
interface is used differentially by IFN-β compared 
to IFN-α1. Furthermore, we show that this interface 
significantly influences the affinity of IFN-β for 
IFNAR1, the IFN-β-mediated internalization of 
IFNAR1, activation of STAT1 and the induction of 
interferon stimulated genes (ISGs). Importantly, 
we also show that this interface influences the 
magnitude of the biological activities that result 
from the IFN-β-IFNAR1 interaction.  
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RESULTS 
The structural determination of murine IFNAR1 
receptor in complex with IFN-β (PDB code 
3WCY) revealed the interaction to be dominated by 
the three membrane-distal domains of the receptor 
with each contributing approximately a third of the 
binding interface (Fig. 1A). By contrast, the fourth 
domain of IFNAR1 contributed just 5% to the 
overall interface (Fig. 1A). We sought to 
understand the relative importance of IFNAR1 
subdomains and individual IFN-β-IFNAR1 
residues (Fig. 1B, C) to the formation of this high 
affinity complex, and the contributions these 
residues made to the functionality of IFN-β via 
IFNAR1. 
IFNAR1-SD3 is vital for efficient IFN-β 
binding—To assess the relative importance of SDs 
of IFNAR1-ECD to IFN-β binding, we generated 
truncation variants of IFNAR1-ECD by 
introducing stop codons at the C-termini of SD3 (to 
generate IFNAR1-SD123) and of SD2 (to generate 
IFNAR1-SD12) (Fig. 1D). Using Native PAGE, 
we compared the ability of these truncated forms 
and the full length IFNAR1-ECD to bind IFN-β 
under native conditions. As we have previously 
shown, the addition of IFN-β induces an observable 
shift in mobility of IFNAR1-ECD (11). A similar 
observable shift in mobility was also seen with the 
addition of IFN-β to IFNAR1-SD123, indicating 
that IFN-β bound this truncated form of IFNAR1-
ECD under these conditions (Fig. 1E). However, 
the addition of IFN-β to IFNAR1-SD12 did not 
alter the mobility of this form of IFNAR1-ECD, 
indicating that IFN-β did not bind this protein 
efficiently under these conditions (Fig. 1E). These 
data suggest that under native PAGE conditions the 
presence of SD3 of IFNAR1-ECD was critical for 
efficient binding of IFN-β. 
Two residues, Y240 and Y274, dominate the 
interaction interface on IFNAR1-ECD SD3—
Examination of the contacts between IFNAR1-
ECD and IFN-β in the crystal structure of the IFN-
β-IFNAR1 complex revealed that central to the 
binding of IFNAR1-SD3 were the residues Y240 
and Y274. Using the AREA/MOL program from the 
CCP4 suite (13), we determined that these residues 
together contributed 40% of the total binding 
interface of this subdomain (Fig. 1B). Y240, located 
on the loop between the β3 and β4 strands of 
IFNAR1-SD3, was pivotal to binding the C-
terminal of the IFN-β B helix and N-terminal of the 
IFN-β C helix. Y240 sat in a predominantly 
hydrophobic pocket of IFNAR1-SD3 with 
principal interactions to IFN-β residues F63, V81, 
L84, and H88 (Fig. 1C).  IFNAR1 Y274, located on 
the loop between the β5 and β6 strands of IFNAR1-
SD3, was similarly pivotal to binding the N-
terminal of the C helix of IFN-β and sat in a polar 
pocket characterized by a hydrogen bond to E77 and 
by van de Waals interactions with T78, V81, and R82 
(Fig. 1C).  
IFNAR1 residues Y240 and Y274 are 
important for IFN-β affinity—We expressed 
recombinant forms of IFNAR1-ECD containing 
mutations at Y240, Y274 or both, generating 
IFNAR1-ECD Y240A, IFNAR1-ECD Y274A, and 
IFNAR1-ECD Y240A/Y274A (herein referred to 
as IFNAR1-ECD YYAA), respectively (Fig. 2A). 
We assessed the binding of IFN-β to these receptor 
variants using surface plasmon resonance (SPR). 
Our results show that while alanine substitutions at 
Y240 or Y274 showed slight but not statistically 
significant reductions in IFN-β binding (Table 1), a 
synergistic effect was observed when these two 
mutations were combined in IFNAR1-ECD 
YYAA. The affinity of IFN-β for IFNAR1-ECD 
YYAA was significantly reduced ~69-fold when 
compared with IFN-β binding to IFNAR1-ECD 
(Table 1). These data suggest that individually Y240 
and Y274 make minor contributions to IFN-β 
binding and affinity for IFNAR1-ECD, but that 
together they have a synergistic effect, dramatically 
influencing the interaction.  
Mutations introduced onto IFN-β 
differentially affect IFNAR1 affinity—Since we had 
demonstrated the importance of IFNAR1 residues 
Y240 and Y274 to this interface, we next investigated 
the importance of IFN-β residues that bind these 
tyrosine residues to this interface. We generated 
variants of IFN-β by substituting alanine residues 
pairwise at either F63L64, E77T78, or V81R82, the 
residues predicted to be the central contacts 
between IFN-β and IFNAR1 residues Y240 and Y274 
(Fig. 2B). We also generated a multi-site variant of 
IFN-β by substituting alanine residues at the six 
residues above, generating IFN-β variant 
F63A/L64A/E77A/T78A/V81A/R82A, herein 
referred to as IFN-β FLETVR (Fig. 2B). As these 
residues are predominantly hydrophobic (F, L, T, 
V) or ionic (E, R), their collective mutation may 
compromise the high affinity binding of the IFN-β-
IFNAR1 interaction. Initially, circular dichroism 
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(CD) spectroscopy was used to compare the overall 
fold of IFN-β and its variants and demonstrated that 
the single- and multi-site alanine substitutions 
introduced onto IFN-β did not alter the α-helical 
structure of the proteins (Fig. 2C).  
We next used SPR to measure the affinity 
of IFN-β and its variants to IFNAR1-ECD. 
Comparison of the measured affinities of IFN-β 
and the IFN-β variants to immobilized IFNAR1-
ECD showed that none of the single site variants 
IFN-β FL63AA, IFN-β ET77AA or IFN-β 
VR81AA showed a significant reduction in affinity 
for IFNAR1 compared to IFN-β (Table 1). By 
comparison, the multi-site variant IFN-β FLETVR 
showed a significant ~165-fold reduction in 
IFNAR1 affinity (Table 1). Overall, these results 
suggest that, although the mutations introduced at 
F63L64, E77T78 and V81R82 had insignificant effects 
on IFNAR1 affinity, the combination of all six 
residues had the greatest effect on affinity of IFN-
β for IFNAR1. 
IFNAR1 residues Y240 and Y274 are 
important for IFN-β-mediated signaling—To 
compare the contributions made by residues Y240 
and Y274 to signal transduction by IFN-β, we 
generated variants of full length IFNAR1 housing 
tyrosine to alanine mutations at Y240 
(IFNAR1Y240A), at Y274 (IFNAR1Y274A) or at 
both residues (IFNAR1Y240A/Y274A herein 
referred to as IFNAR1YYAA) (Fig. 2A). We used 
transient transfection of Ifnar1-/- MEFs to express 
full-length IFNAR1 or the variants above on the 
surface of these cells. We confirmed the presence 
of equivalent levels of IFNAR1 mRNA in the 
transfected Ifnar1-/- MEFs using RT-PCR 
(Supplemental Fig. S1)). Our data showed that after 
treatment with IFN-β, cells transfected with all 
IFNAR1 variant receptors showed a reduced 
Interferon Stimulated Response Element (ISRE)-
luciferase response compared to cells transfected 
with IFNAR1 (Fig. 3A; P<0.01). Cells transfected 
with either IFNAR1Y240A or IFNAR1Y274A 
showed relatively minor differences in the 
luciferase response (showing 20% and 28% 
reductions, respectively, P<0.01), whereas cells 
transfected with IFNAR1YYAA demonstrated an 
85% reduction in luciferase response compared to 
that measured by IFN-β stimulation through the 
IFNAR1 receptor (Fig. 3A, P<0.001). To 
investigate IFN subtype specificity of the interface 
on IFNAR1-SD3 we assessed the use of IFNAR1 
receptor variants for signaling by IFNα. Our data 
show that compared to IFNAR1, transfection of 
cells with IFNAR1Y240A or IFNAR1YYAA 
reduced IFNα-driven ISRE-luciferase responses in 
these cells by 91% and 100%, respectively (Fig. 
3B). By contrast, cells transfected with 
IFNAR1Y274A showed a 33% reduction (relative 
to IFNAR1) in the IFNα-driven ISRE-luciferase 
response (Fig. 3B). Comparison of the pattern of 
IFN-β- and IFN-α-induced ISRE-luciferase 
responses transduced via IFNAR1Y240A was 
remarkably different between these IFN subtypes, 
suggesting that the interface on IFNAR1-SD3, 
incorporating both Y240 and Y274, is used 
differentially by IFN-β compared to IFN-α.  
IFN-β residues binding IFNAR1 Y240 and 
Y274 are important for signaling—Having shown 
that the IFN-β variant proteins retained their native 
fold and that some demonstrated reduced affinity 
for IFNAR1-ECD, we next assessed their ability to 
signal by driving an ISRE-luciferase reporter in a 
transient transfection system. We transfected 
Ifnar1-/- MEFs with IFNAR1 and stimulated these 
cells with 2.5 ng/mL of either IFN-β, IFN-β 
FL63AA, IFN-β ET77AA, IFN-β VR81AA, or 
IFN-β FLETVR. Our results showed that 
stimulation of cells with the single-site variants, 
IFN-β FL63AA, IFN-β ET77AA and IFN-β 
VR81AA, showed a trend to reduction in the 
induced luciferase response that was not 
significantly different from cells stimulated with 
IFN-β (Fig. 3C). In contrast, cells treated with IFN-
β FLETVR induced a consistent and significantly 
reduced luciferase response (reduced by 45%) 
compared to cells stimulated with IFN-β (Fig. 3C). 
Although none of the single-site IFN-β variants 
showed a significant contribution to the IFN-β-
induced ISRE-luciferase response, these data 
suggest that IFN-β residues F63L64, E77T78 and 
V81R82 cooperate to synergistically support IFN-β-
driven signaling via the critical IFNAR1-SD3 
interface. 
The IFN-β-IFNAR1-SD3 interface controls 
down regulation of endogenous IFNAR1—Having 
shown that the combined substitutions introduced 
onto IFN-β significantly affected both IFNAR1 
binding affinity and signaling, we next measured 
their effect on the down regulation of IFNAR1 
from the surface of cells (11,14). We observed that 
IFN-β significantly reduced surface levels of 
IFNAR1 in a dose-dependent manner and at all 
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doses investigated (Fig. 4A). In comparison, IFN-β 
FLETVR did not significantly remove IFNAR1 
from the surface of cells, even at doses 30 times 
higher than IFN-β (at 0.3 ng/ml) which did induce 
significant IFNAR1 downregulation (Fig. 4A). 
Since IFN-β FLETVR showed a lower binding 
affinity for IFNAR1 than IFN-β, we assessed 
whether the lack of observable IFNAR1 down 
regulation may be due to the short time course of 
this experiment (1 hour) and carried out an 
experiment over 48 hours of continuous IFN-β or 
IFN-β FLETVR stimulation. Again, IFN-β 
treatment down regulated IFNAR1 from the 
surface of the cells, and maintained reduced levels 
of surface IFNAR1 until at least 24 hours after 
initiation of treatment; by 48 hours of treatment the 
levels of IFNAR1 on the surface of the cells had 
returned to levels measurable on untreated cells 
(Fig. 4B). In comparison, cells treated with IFN-β 
FLETVR did not show any significant reduction in 
IFNAR1 surface levels, throughout the 48 hour 
time-course (Fig. 4B). These data suggest that the 
residues of IFN-β mutated to generate the IFN-β 
FLETVR variant are crucial for the IFN-β-driven 
down-regulation of endogenous IFNAR1 from the 
cell surface. 
The IFN-β-IFNAR1-SD3 interface governs 
STAT1 activation and gene induction—Since our 
results had shown that the IFN-β FLETVR variant 
had a reduced ability to activate the STAT 
responsive ISRE reporter, we next determined 
whether IFN-β FLETVR could activate STAT1 via 
the endogenous IFNAR1 receptor on mouse cells. 
Our results showed that stimulation of cells with 
IFN-β induced rapid phosphorylation of STAT1 
Y701 within 30 minutes of treatment, with no 
discernible difference between the low (1 ng/ml) 
and high (5 ng/ml) doses applied (Fig. 5A, B); a 
significant reduction in IFN-β induced STAT1 
phosphorylation was evident after 120 minutes. 
Following stimulation with IFN-β FLETVR, we 
observed reduced STAT1 phosphorylation after 30 
minutes of treatment compared to cells treated with 
IFN-β at both doses (1 and 5 ng/mL); STAT1 
phosphorylation was barely detectable after 120 
minutes (Fig. 5A, B). Overall, our results show that 
although IFN-β FLETVR could induce some 
STAT1 phosphorylation, levels were significantly 
reduced compared to those measured in cells 
treated with IFN-β (Fig. 5A, B). 
We next investigated whether IFN-β 
FLETVR could induce the expression of ISGs in 
mouse cells. IFN-β induced the expression of all 
ISGs investigated (Ccl2, Cxcl10, Ccl7, Ifit1, Irf1, 
Bst2, Irf7, Stat1 and Oas2) with different dose-
dependencies (Fig. 6). In comparison, the 
magnitude of ISG induction was significantly 
reduced upon stimulation with IFN-β FLETVR 
(Fig. 6). We observed that IFN-β FLETVR induced 
some ISGs (Ccl2, Ccl7, and Cxcl10) at levels not 
significantly different from those measured in 
untreated cells, suggesting that efficient induction 
of these genes is reliant on a high affinity IFN-β-
IFNAR1 interaction (Fig. 6). Interestingly, for 
another subset of genes – Ifit1, Irf1, Bst2, Irf7, 
Stat1, and Oas2 – we observed induction by IFN-β 
FLETVR in a dose dependent manner, but 
significantly less than that observed with IFN-β 
(Fig. 6). Taken together, these data suggest that the 
residues mutated to generate IFN-β FLETVR are 
important for efficient IFN-β-driven STAT1 
phosphorylation and gene induction.  
The IFN-β-IFNAR1-SD3 interface 
regulates ligand-dependent biological activities—
We next investigated the effect that these mutations 
and the resultant altered downstream signaling 
events had on the biological activities elicited by 
the IFN-β FLETVR variant. We compared the anti-
viral and anti-proliferative activities of IFN-β and 
the IFN-β FLETVR variant. Compared to the 
specific anti-viral activity of IFN-β, IFN-β 
FLETVR demonstrated a ~186-fold reduction in its 
ability to protect mouse cells from infection by 
Semliki Forest Virus (SFV) (Fig. 7A) suggesting 
that the IFNAR1-SD3 interface influences the anti-
viral properties of IFN-β. 
To assess the effect of IFN-β mutations on 
the anti-proliferative capacity of the protein, we 
compared the ability of IFN-β and IFN-β FLETVR 
to inhibit the proliferation of a mouse cell line. In 
this assay, IFN-β induced ~80% inhibition in 
cellular proliferation even at the lowest dose 
applied (Fig. 7B). In comparison, although 
treatment of cells with IFN-β FLETVR also 
showed a dose response in inhibition of cellular 
proliferation (Fig. 7B), the extent of inhibition was 
significantly reduced compared to that induced by 
IFN-β (Fig. 7B). These results suggest that the 
interface on IFNAR1-SD3 also influences the 
ability of IFN-β to inhibit cellular proliferation. 
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DISCUSSION  
IFN-β plays important roles in activating 
innate and adaptive immunity, however excessive 
IFN-β signaling has been implicated in the 
pathogenesis of several diseases.  Detrimental roles 
for IFN-β and/or its receptor IFNAR1 have been 
described during sepsis (15-17), bacterial 
infections including Listeria and Mycobacterium 
spp. (18), parasitic infections caused by 
Trypanosoma and Leishmania spp. (18), chronic 
viral infection (8,19) and in the transmission of 
neuropathic pain (20). It has been hypothesized that 
a targeted reduction in IFN-β-IFNAR1 signals may 
be sufficient to protect the host against the lethality 
of experimental sepsis (21). We previously 
characterized the importance of IFN-β binding to 
IFNAR1 in pro-inflammatory responses and here 
we identified a key interaction interface mediated 
by two residues on IFNAR1, Y240 and Y274, which 
interact with particular residues on IFN-β (F63, L64, 
E77, T78, V81, and R82). We demonstrated that this 
interface stabilizes the ligand-receptor complex, 
and influences all aspects of IFN-β functionality 
suggesting that this interface may be a suitable 
target for rational drug design to therapeutically 
modulate IFN-β-mediated signaling.  
 We and others have shown that the 
minimal ligand binding region for IFNs on 
IFNAR1 generally exists on the three membrane 
distal subdomains of this receptor (12). More 
specifically for IFN-β, we have further shown that 
the interface spanning both Y240 and Y274 on 
IFNAR1-SD3 is most vital to IFNAR1 binding and 
IFN-β function. Since both these residues made 
multiple interactions with residues on IFN-β, not 
just via their hydroxyl groups, we chose to replace 
both residues with alanine to generate the most 
unambiguous results. Of these residues, Y240 is well 
conserved across species (Supplementary Fig 
S2A); our data clearly demonstrate a greater 
reliance on this residue for efficient IFN-α- 
compared to IFN-β-mediated signal transduction, 
an observation that is supported in the literature 
(10). The second tyrosine residue we identified in 
the interface on IFNAR1-SD3, Y274, is not 
conserved across species (Supplementary Fig 
S2A); indeed the residue to which it aligns in 
human IFNAR1 (Q272) was not identified as 
important in the IFN-ω-IFNAR1 interface (10). 
Our data, however, suggests that IFN-β and IFN-α 
both partially utilize this residue on mouse IFNAR1 
for an efficient ISRE-dependent response. That 
IFN-β seems to utilize this residue in synergy with 
Y240 for efficient signal transduction suggests that 
the interface spanning these two residues may be a 
site of species or IFN subtype specificity.  
From the ligand perspective, residues we 
identified as important in the mouse IFN-β-
IFNAR1-SD3 interface are variably conserved 
across species and/or IFN subtype (Supplementary 
Fig S2B). F63, E77 and T78 are highly conserved 
across IFN subtype and species; whilst the homolog 
to F63 in human IFN-ω (F67) is important in the IFN-
ω-IFNAR1 interface, the residues to which E77 and 
T78 align (M81 and T82, respectively) were not 
identified as important to the IFN-ω-IFNAR1 
interaction, supporting the potential involvement of 
this site in the ligand discrimination mechanism 
exhibited by IFNAR1 (10). Indeed, E77, T78 and R82 
in the IFN-β-IFNAR1-SD3 interface bind 
exclusively to Y274 of IFNAR1 (11), further 
supporting the unique dependence on this tyrosine 
residue for IFN-β-mediated signaling. While the 
presence of a valine at position 81 (V81) seems to 
be unique to mouse IFN-β, the residue to which V81 
structurally aligns in human IFN-ω (D85) has been 
shown to be involved in the hIFNAR1 interface 
(10). Disparity in the reduction in signals 
transduced by IFNAR1 residues versus IFN-β 
residues (F63, L64, E77, T78, V81, and R82) in the IFN-
β-IFNAR1-SD3 interface suggests that other 
residues on IFN-β may also contribute to signaling.  
Other studies have reported that IFNs with 
a comparatively lower binding affinity for IFNAR1 
show reductions in the ability to down-regulate 
cell-surface IFNAR1 (22,23), to activate STAT1 
and to exert an anti-proliferative response on cells 
(23). Our findings are consistent with these 
observations in that targeted abrogation of the high 
affinity IFN-β-IFNAR1 complex completely 
abolished down-regulation of endogenous IFNAR1 
and activation of these IFN-β-mediated signaling 
outcomes. From the ligand perspective, our data 
showed a correlative effect between IFN-β-
IFNAR1 binding affinity and the significance of the 
IFN-β-driven STAT response. These data 
demonstrate the cumulative effect of IFN-β 
residues F63, L64, E77, T78, V81, and R82 to these 
biological outcomes of the IFN-β-IFNAR1 
interaction. Since we showed that this interface 
influenced the magnitude of the STAT1-
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phosphorylation dependent signaling which has 
been shown to be vital for protection of cells 
against viral infection, our findings are also 
consistent with a role for the identified interface in 
the anti-viral activity of IFN-β (24). The IFNAR1 
and IFNAR2 binding interfaces on the type I IFNS 
are located on opposing sides of the ligands and 
seem somewhat independent of each other (10).  So 
although the residues we targeted in this study were 
found exclusively within the IFN-β-IFNAR1-SD3 
interface we do not expect the mutations made to 
IFN-β to have effected its interaction with 
IFNAR2. However, this remains to be 
experimentally determined.  
Since we had shown that the IFN-β-
IFNAR1-SD3 interface influenced the magnitude 
of STAT1 activation, for investigation of its effect 
on gene induction we targeted ISGs that had been 
reported to be inducible via phospho-STAT1 
independent pathways, such as the un-
phosphorylated STAT1 pathway (24). Analysis of 
the genes induced by IFN-β in our study revealed 
that there was one subset of genes (Ccl2, Cxcl10, 
Ccl7, Ifit1, and Irf1) reliant on the high affinity 
IFN-β-IFNAR1 interaction for efficient gene 
induction, an observation supported by the 
literature (23,25-27). Interestingly, the subset of 
genes previously identified as inducible via an IFN-
β-dependent, un-phosphorylated STAT1 mediated 
anti-viral pathway (Bst2, Irf7, Stat1, and Oas2) 
were less effected by the mutations made to the 
IFN-β-IFNAR1-SD3 interface (24). Our results 
therefore suggest that this pathway may be only 
partially dependent on the high-affinity IFN-β-
IFNAR1-SD3 interface identified. We found that 
mutations made to this interface impacted not only 
ISG induction but also the ability of IFN-β to 
inhibit cellular proliferation, as evident from the 
reduced dose-response curve of the IFN-β-IFNAR1 
variant. Mechanistically, these results may 
therefore point to a role for the identified IFN-β-
IFNAR1-SD3 interface in differentially regulating 
or mediating alternative IFN-β-IFNAR1-driven 
signaling events or pathways. Our data, 
demonstrating the functional importance of 
residues at the IFN-β-IFNAR1-SD3 interface are in 
contrast to alanine mutations introduced to the 
(juxta) transmembrane region which predictably 
had no effect on IFN binding affinity or signaling 
(28).  
Overall, we have characterized and 
identified an important binding interface between 
IFN-β and IFNAR1 that is critical for eliciting the 
full biological response resulting from IFN-β 
engagement of IFNAR1 – from initial binding to 
the receptor, to receptor internalization, 
transcription factor activation, gene induction and 
biological processes. Importantly, we demonstrated 
that by modulating this interface we can distinctly 
alter the biological effects of IFN-β. Thus, in 
identifying an IFN-β-specific interface on IFNAR1 
and elucidating its importance in modulating IFN-
β-mediated responses, we provide further insight 
into how this cytokine functions and reveal an 
important target for drug discovery to fine-tune 
IFN-β-driven responses and perhaps mediate 
subsequent disease. 
EXPERIMENTAL PROCEDURES 
Cell lines and Cell Culture—Mouse L929 
fibroblast cell line was purchased from the 
American Type Culture Collection and maintained 
in RPMI 1640 medium supplemented with 10% 
(v/v) fetal calf serum (Gibco), 50U/mL penicillin, 
50U/mL streptomycin (Gibco) at 37oC, 5% (v/v) 
CO2. Mouse embryonic fibroblasts (MEFs) were 
derived from Ifnar1-/- mice as previously published 
(29) and maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) containing 10% (v/v) fetal calf 
serum (Gibco), 50U/mL penicillin, 50U/mL 
streptomycin (Gibco) at 37oC, 5% (v/v) CO2. 
Serum-free adapted insect cell lines Sf9 and High 
FiveTM (BTI-TN-5B1-4 from Trichoplusia ni) were 
purchased from Life Technologies and maintained 
in Sf900-II SFM media (Life Technologies) 
supplemented with 1 µg/mL Gentamicin (Sigma-
Aldrich) in a shaking incubator at 27°C, 120 rpm. 
For expression cultures, High FiveTM cells were 
diluted in serum-free Express Five media (Life 
Technologies) supplemented with 20mM L-
Glutamine (Sigma) and 1 µg/mL Gentamicin 
(Sigma) and incubated at 27°C, 120 rpm.  
Constructs and cloning—The clone of 
mIFNAR1-ECD was as previously reported (11). 
Constructs encoding truncation variants of 
IFNAR1-ECD were generated using this clone and 
the QuikChange mutagenesis kit (Stratagene) to 
introduce stop codons at the junctions between 
IFNAR1-ECD subdomains as directed by specific 
primer pairs (Table 2). Site-directed mutagenesis 
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was also carried out to introduce alanine mutations 
at amino acid positions Y240 and Y274 of this 
IFNAR1-ECD clone (Table 2). The mIFN-β clone 
was as previously reported (30). Site-directed 
mutagenesis was carried out using the QuikChange 
mutagenesis kit (Stratagene) to introduce pair-wise 
alanine mutations at amino acid positions F63/L64, 
E77/T78, and V81/R82 of this IFN-β clone as required 
(Table 2).  
Recombinant protein expression, 
purification and Native PAGE—All recombinant 
IFNAR1-ECD and IFN-β forms were expressed 
using a baculoviral expression system and purified 
as previously published (11,30). The mIFN-α1 
utilized in this project was expressed by transient 
transfection in HEK293S cells and purified from 
culture supernatants as previously described (31). 
The purity of all protein preparations was checked 
on reducing SDS-PAGE prior to use in 
experiments. All interactions and Native PAGE 
were carried out as previously published (11) using 
8% polyacrylamide gels.  
CD Spectroscopy—CD spectral analyses 
were measured at room temperature in a Jasco J815 
CD spectrophotometer. All scans were run on 
proteins concentrated to 130μg/mL in TBS (10mM 
Tris, pH 8.0, 150 mM sodium chloride). Triplicate 
scans were run between 190 and 260 nm. Data were 
collected and converted to mean residue ellipticity 
(MRE) by the equation of Correa and Ramos (32). 
Data is representative of triplicate experiments. 
SPR —All SPR experiments were carried 
out on a ProteOn XPR36 (Bio-rad Labs) using a 
HTG chip for His-tagged proteins and TBS as the 
running buffer. All ligands (IFNAR1-ECD and 
variants) were immobilized to the nickel activated 
chip via the His-tags after dilution to 25 µg/mL in 
TBS (10mM tris, pH 8.0, 150 mM sodium 
chloride). All analyte samples (IFN-β and variants) 
were diluted in TBS to various concentrations 
ranging from 40 nM to 1 uM. All data were 
referenced according to the manufacturer’s 
instructions (Bio-Rad) and analyzed using the 
Langmuir binding model. Data were considered for 
inclusion in the analysis only if the Chi2 value (the 
measure of error between measured and fitted 
values) was less than 10% of the Rmax as per the 
manufacturer’s instructions (Bio-Rad). ka (1/Ms), 
kd (1/s), and KD (nM) were calculated by the 
Proteon Manager software and are represented as 
mean from at least triplicate experiments. 
Significance was determined using one-way 
ANOVA with Dunnett’s multiple comparisons 
testing. 
Transient transfections of Ifnar1-/- MEFs 
and luciferase assays—Ifnar1-/- MEFs were used 
for all transient transfections of IFNAR1 or its 
variants as previously reported (33). Cells were 
incubated at 37oC, 5% (v/v) CO2 for ~20 hours 
prior to the addition of any stimuli. To test for 
comparative expression of introduced Ifnar1 
mRNA, cells were harvested after the 20 hours 
incubation without any stimulation. For luciferase 
assays, we co-transfected an ISRE-luciferase 
reporter (as previously published in (33)) as a 
measure of STAT activation induced by IFN 
stimulations. All stimulations were carried out with 
continuous IFN treatment (2.5 ng/mL of culture), 
with cells harvested for luciferase assays after 4 
hours incubation at 37oC, 5% (v/v) CO2. After 
incubation, cells were lysed in passive lysis buffer 
(Promega); luciferase and TK-Renilla activity were 
assessed as previously described (33). All 
transfections were carried out in at least biological 
and technical triplicate for each sample with 
readings normalized to that of TK-Renilla. Results 
are presented as luminescence measurable per 
treatment above those measured in cells transfected 
with vector alone, and then converted to percentage 
of the luciferase response measured on cells 
transfected with IFNAR1 and treated with IFN. 
Significance of responses were calculated using a 
2-way ANOVA with Tukey’s multiple 
comparisons testing. 
Cell lysis, SDS-PAGE and Western blot—
We used L929 cells stimulated with IFN-β or the 
IFN-β FLETVR variant to compare the ability of 
these proteins to induce phosphorylation of STAT1 
(at Y701). Cells were plated at 6 x 105 cells per well 
of a 6 well cell culture dish and incubated overnight 
at 37oC, 5% (v/v) CO2. After the end-point of 
stimulation, media was aspirated, cells rinsed with 
PBS and lysed in cell lysis buffer as previously 
reported (11). Protein concentrations in cell lysates 
were quantified using Lowry reagents (Bio-rad) 
and assayed using a FLUOstar Optima microplate 
reader (BMG Technologies). Seven to 15 µg of 
whole cell lysate was separated on a 10% (v/v) 
SDS-PAGE (34) and transferred to PVDF 
membrane (Immobilon FL, Millipore) using a Mini 
Trans-Blot apparatus (Bio-rad). Membranes were 
blocked in Odyssey blocking buffer (OBB; 
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Millenium Sciences) for 1 hour at 22oC. 
Membranes were incubated with primary 
antibodies (anti-phospho-Y701 STAT1 (Cat No 
7649S, clone D4A7; 1:1000, Cell Signaling 
Technologies), total anti-mouse STAT1 (Cat No 
sc-346, clone E-23; 1:200, Santa Cruz 
Biotechnologies) or anti-actin antibodies (Cat No 
A4700, clone AC-40; 1:500, Sigma)) diluted in 
fresh OBB for 16 hours at 4oC. Binding of 
secondary antibodies (AlexaFluor 680-conjugated 
anti-mouse IgG (1:1000, Cat No A21057, Life 
Technologies); IR800-conjugated anti-rabbit IgG 
(1:1000, Cat No 611-145-002-0 5, Rockland)) 
diluted in OBB was carried out for 1 hour at 22oC. 
Antibody binding was detected using an Odyssey 
Infra-Red Imager (Li-Cor). Densitometry of the 
detected bands was quantitated using ImageJ; the 
levels of detectable phospho-STAT1 were 
normalized to the level of actin for each sample 
(triplicate experiments). The blots shown are 
representative of triplicate independent 
experiments. Significance of responses were 
calculated using a 2-way ANOVA with Tukey’s 
multiple comparisons testing. 
Extraction of RNA and cDNA synthesis for 
quantitative Real-Time PCR—To evaluate gene 
expression by quantitative real-time PCR (RT-
PCR), L929 cells were plated at 6 x 105 cells per 
well of a 6 well cell culture dish and incubated 
overnight at 37oC, 5% (v/v) CO2. After 3 hours of 
treatment, cells were lysed in RLT buffer and RNA 
purified using the RNeasy column purification kit 
(Qiagen); all cDNA synthesis was prepared using 
Superscript III First Strand cDNA kit (Invitrogen) 
and random hexamers (Invitrogen) following the 
manufacturer’s protocol. Quantitative RT-PCR 
was performed on an Applied Biosystems 7900HT 
Fast Real-Time PCR system (ABI) using Sybr 
reagents (ABI); amplification was directed by the 
forward and reverse primer pairs indicated (Table 
2). All experiments were carried out with biological 
and technical triplicates (except where stated) with 
data normalized relative to the expression of 18S 
and transformed using the ΔΔCT method (35). Data 
are presented as fold induction relative to 
unstimulated control samples and reported as mean 
+ SD of at least triplicate independent experiments. 
Significant difference in fold induction between 
untreated, IFN-β and IFN-β FLETVR treated 
samples was calculated using 2-way ANOVA with 
either Sidak’s multiple comparisons testing (to 
compare mRNA levels measured in IFN-β and 
IFN-β FLETVR treated samples) or Dunnett’s 
multiple comparisons testing (to compare mRNA 
levels measured in all stimulated cells with that in 
untreated cells). 
Flow cytometry—Flow cytometry was 
used to measure and compare the effect of 
stimulation with IFN-β or the IFN-β FLETVR 
variant on surface levels of IFNAR1 on L929 cells. 
The anti-mouse IFNAR1 antibody (Cat No I-401, 
Clone Mar1-5A3, Leinco) was as reported in (36) 
and its isotype counterpart (Cat Nos I536, Clone 
HKSP84, Leinco) were biotinylated using EZTM-
Link NHS-Biotin following the manufacturers’ 
instructions (Thermo Scientific). For flow 
cytometry, L929 cells were plated at 2 x 105 
cells/well of a 24 well culture plate and incubated 
at 37oC, 5% (v/v) CO2 overnight. After stimulation, 
cells were harvested from the culture vessel using 
cell suspension buffer (PBS with 2% (v/v) fetal calf 
serum) containing 5mM EDTA, and then 
centrifuged at 1500 rpm for 5 minutes. Non-
specific antibody interactions were blocked using 
anti-CD16/CD32 blocking antibody (Cat No 14-
0161-86, clone p3; eBiosciences diluted 1:200) 
prior to staining with either biotinylated anti-mouse 
IFNAR1 or the biotinylated isotype control 
antibody both diluted to 10 µg/mL in cell 
suspension buffer. Antibody binding was detected 
using a Phycoerythrin (PE)-conjugated 
Streptavidin secondary antibody (Cat No F0040, 
R&D systems diluted 1:1000). All cell staining was 
analyzed on a FACSCanto II (Becton Dickinson). 
Data are given as mean fluorescence intensity 
(MFI) of anti-mouse IFNAR1 staining above levels 
of isotype control antibody staining, and are 
reported as mean of at least triplicate independent 
biological replicates. Significance of responses 
were calculated using a one-way ANOVA with 
Dunnett’s multiple comparisons testing.  
Anti-viral activity of IFN—Antiviral 
activities of IFN-β and the IFN-β FLETVR variant 
were determined by cytopathic effect inhibition 
assay using mouse L929 cells and SFV for 
infection (37). Activity was measured against a 
National Institutes of Health reference standard 
(GU-02-901-511) as published previously (37) and 
is reported as the concentration of IFN that is 
required to provide protection to 50% of the 
exposed cells (ED50). Data are given as specific 
activity (IU/mg of protein), and are reported as the 
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average from at least triplicate independent 
experiments. Student’s t-test was applied to the two 
groups to determine significance. 
Measurement of anti-proliferative 
activity—For assessment of the ability of IFN-β 
and its variants to inhibit cellular proliferation, 6 x 
104 L929 cells were plated per well of a 96 well E-
plate (Roche Diagnostics) and monitored using the 
xCELLigence Real-Time Cell Analyzer SP 
Instrument (Roche Diagnostics) at 37oC in 5% (v/v) 
CO2. Cell index (CI) measurements were 
performed in quadruplicate per stimulation and 
signal was detected every 30 minutes. For analysis, 
the CI index was normalised to time of treatment 
and the slope (1/h) was calculated from normalised 
CI to 72h post treatment using the Real-Time Cell 
Analyzer software (Version 1.2, Roche 
Diagnostics). All treatment analysis was compared 
to the slope of buffer control treated cells. Data is 
expressed as mean + SD of triplicate independent 
experiments, performed in technical quadruplicate, 
and analyzed using 2-way ANOVA with Sidak’s 
multiple comparisons test.
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FOOTNOTES: The abbreviations used are: IFNAR, IFN-α/β receptor; SD, subdomain; STAT, Signal 
transducer and Activator of Transcription; ECD, extracellular domain; ISGs, interferon stimulated genes; 
N-terminal, amino-terminal; C-terminal, carboxyl-terminal; SPR, Surface Plasmon Resonance; CD, 
Circular Dichroism; MEFs mouse embryonic fibroblasts; ISRE, interferon stimulated response element; 
PE phycoerythrin; SFV, Semliki Forest Virus; DMEM, Dulbecco’s Modified Eagle Medium; TBS, tris-
buffered saline; MRE mean residue ellipticity; RT-PCR, quantitative real-time PCR; MFI, mean 
fluorescence intensity; ANOVA, Analysis of variance; CI, cell index; OBB Odyssey blocking buffer. 
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Table 1. Surface Plasmon Resonance (SPR) measurements of IFN-β and mutants binding to IFNAR1 and the mutant receptors as indicated. Association (ka), 
Dissociation (kd) and Affinity (KD) are indicated. Data are represented as mean + SEM of a least triplicate independent experiments. Significance of 
comparisons calculated relative to the KD of the IFNAR1-IFN-β interaction. **** P < 0.0001 (1-way ANOVA with Dunnett’s multiple comparisons testing).  
 
Receptor IFN ka (1/Ms) 
(Mean) 
kd (1/s) 
(Mean) 
KD (nM) 
(Mean + SD) 
Fold increase (KD) 
compared to IFNβ 
Significance 
(KD) from IFNβ 
       
IFNAR1-ECD IFN-β 1.55 x 105 3.77 x 10-4 3.34 (+ 2.23) 1 - 
IFNAR1-ECDY240A IFN-β  4.66 x 105 
 
1.16 x 10-2 
 
29.1 (+ 15.5) 
 
8.71 NS  
IFNAR1-ECDY274A IFN-β 5.39 x 104 
 
8.58 x 10-4 20.6 (+ 12) 6.17 NS 
IFNAR1-ECDYYAA IFN-β 4.07 x 105 
 
9.79 x 10-2 
 
232 (+ 67.2) 69.46 **** 
       
IFNAR1-ECD IFN-β FL63AA 7.40 x 105 7.85 x 10-3 16.8 (+ 5.65) 3.00 NS 
IFNAR1-ECD IFN-β ET77AA 8.87 x 104 8.51 x 10-4 12.1 (+ 5.8) 3.62 NS 
IFNAR1-ECD IFN-β VR81AA 5.27 x 105 1.76 x 10-3 7.44 (+ 3.72) 2.22 NS 
IFNAR1-ECD IFN-β FLETVR 9.86 x 104 4.65 x 10-2 552 (+ 175) 165.27 **** 
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Table 2. Primers utilised in this study, and the purpose for which they were used. 
Primer name or 
purpose 
Primer Sequence 5’ to 3’ 
Forward 
Primer Sequence 5’ to 3’ 
Reverse 
MUTAGENESIS   
Introduce stop codon 
at V205 in IFNAR1 
NA CTTGGAGATTTCCTGGTCAAGGCATTTTATTTGC 
Introduce stop codon 
at P309 in IFNAR1 
NA GTTAAGCTTAAGGAGGGAGAATGTGTTT 
IFNAR1 Y240 to A GTGGCTTCCTGGCGCTTCAAAAAGCAG CTGCTTTTTGAAGCGCCAGGAAGCCAC 
IFNAR1Y274 to A CTCAAGATACTGTCGCCACAGGAACGTTCTT
TCTC 
GAGAAAGAACGTTCCTGTGGCGACAGTATCTTG
AG 
IFN-β F63/L64 to 
AA to IFN-β 
FL63AA 
GAGTGCTCCAGAATGTCGCTGCTGTCTTCAG
AAACAATTTC 
GAAATTGTTTCTGAAGACAGCAGCGACATTCTG
GAGCATCTC 
IFN-β E77/T78 to 
AA to IFN-β 
ET77AA 
CTCCAGCACTGGGTGGAATGCGGCTATTGTT
GTACGTCTCCTG 
CAGGAGACGTACAACAATAGCCGCATTCCACCC
AGTGCTGGAG 
IFN-β V81/R82 to 
AA to IFN-β 
VR81AA 
GGAATGAGACTATTGTTGCAGCTCTCCTGGA
TGAACTCCAG 
GTGGAGTTCATCCAGGAGAGCTGCAACAATAGT
CTCATTCC 
IFN-β to ET77AA on 
IFN-β V81/R82aa 
backbone to generate 
FLETVR 
CTCCAGCACTGGGTGGAATGCGGCTATTGTT
GCAGCTCTCCTG 
CAGGAGAGCTGCAACAATAGCCGCATTCCACCC
AGTGCTGGAG 
   
RT-PCR   
m18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
mOas1a CCTGCACAGACAGCTCAGAA AGCCACACATCAGCCTCTTC 
mISG15 TGAGAGCAAGCAGCCAGAAG ACGGACACCAGGAAATCGTT 
mIRF7 ATCTTGCGCCAAGACAATTC AGCATTGCTGAGGCTCACTT 
mBst2 GGAGTCCCTGGAGAAGAAGG GGAGTCCCTGGAGAAGAAGG 
mCCL2 AGGTGTCCCAAAGAAGCTGTA ATGTCTGGACCCATTCCTTCT 
mCCL7 AGATCCCCAAGAGGAATCTCA ATAGCCTCCTCGACCCACTT 
mCXCL10 CTGAATCCGGAATCTCCGACC GAGGCTCTCTGCTGTCCATC 
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mIfit1 TCAAGGCAGGTTTCTGAGGA ACCTGGTCACCATCAGCATT 
mIrf1 AGCTGCAAAGAGGAACCAGA CTCACAGAGTTGCCCAGCAG 
mStat1 TCACATTCACATGGGTGGAA CGGCAGCCATGACTTTGTAG 
mIfnar1-Neo GTGGGCACTGGAGAAACCT TGACGGATGTATTGCTTTAACTTCT 
mIfnar1 GCAGTGTGACCTTTTCAGCA GAGAATTCACACTTGGTCGTTG 
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FIGURE LEGENDS 
 
FIGURE 1. Contributions of IFNAR1 subdomains (SD) 1-4 to IFN-β binding. (A) The crystal structure 
of IFNAR1 (blue) in complex with IFN-β (yellow). Relative percentage contributions of each domain 
of IFNAR1 to the overall IFN-β binding interface (crystal structure of the IFN-β-IFNAR1 complex 
from (11); PDB code 3WCY). (B) The helices of IFN-β (A to E) and the IFNAR1 subdomains (SD1-
4) are indicated. The positions of Y240 and Y274 are indicated with dark blue spheres. (C) Close-up view 
of the binding of Y240 and Y274 (blue sticks) to residues on the B and C helices of IFN-β (yellow sticks). 
(D) Diagrammatic representation of IFNAR1-ECD truncation variants generated in this study. (E) 
Native PAGE (10% v/v) analysis of IFNAR1-ECD, IFNAR1-SD123, IFNAR1-SD12 alone and with 
IFN-β. These interactions were carried out in triplicate. 
FIGURE 2. IFNAR1 and IFN-β variants generated and assessed in this study. (A) Residues of IFNAR1 
were mutated to alanine residues as indicated. IFNAR1 residues 230 to 280 only are shown. (B) 
Residues of IFNβ were mutated to alanine residues as indicated. IFN-β residues 60 to 90 only are shown. 
(C) Circular Dichroism analysis confirmed the α-helical fold of IFN-β variants: IFNβ ( ), IFNβ 
FL63AA ( ), IFNβ ET77AA ( ), IFNβ VR81AA ( ) and IFNβ FLETVR ( ).  
FIGURE 3. IFN specificity and signalling via IFNAR1-ECD SD3 residues. (A, B) Measurement of 
luciferase activity in cells transfected with vector only (VO), IFNAR1, or the IFNAR1 variant receptors, 
IFNAR1Y240A, IFNAR1Y274A, IFNAR1YYAA after stimulation with 2.5ng/mL of either IFN-β (A) 
or mIFNα1 (B) for 4 hours. (C) Measurement of luciferase activity in cells transfected with IFNAR1 
after stimulation with 2.5ng/mL of IFN-β or variants, IFN-β FL63AA, IFN-β ET77AA, IFN-β 
VR81AA, IFN-β FLETVR. Data expressed as mean of at least triplicate independent experiments, all 
performed with technical triplicate. Significance of response calculated relative to cells transfected with 
either IFNAR1 constructs (A, B) or treated with IFN-β (C). * P < 0.05, ** P < 0.01, **** P < 0.0001 
(2-way ANOVA with Tukey’s multiple comparisons testing). Significance of response calculated 
relative to cells transfected with empty vector only # P < 0.05, ## P < 0.01 (2-way ANOVA with 
Tukey’s multiple comparisons testing). 
FIGURE 4. Abundance of surface levels of IFNAR1 on L929 cells treated with either IFN-β or the 
IFN-β FLETVR variant (indicated), as measured by flow cytometry. (A) Cells were treated with 
increasing doses of protein (0.3, 1.0, 2.5, 5.0 and 10 ng/ml) as indicated for 1 hour prior to harvesting 
and staining. (B) Cells were treated with 1 ng/ml of the proteins indicated and harvested after 0.5, 1, 3, 
24 or 48 hours of incubation prior to staining. Data expressed as mean of at least triplicate independent 
experiments, all performed with technical triplicate. Significance of response calculated relative to 
untreated cells (UT). **** P < 0.0001 (1-way ANOVA with Dunnett’s multiple comparisons testing). 
Vertical dashed lines on the X-axes indicate the transition between IFN-β and IFN-β FLETVR 
treatments. 
FIGURE 5. IFN-β FLETVR variant induces reduced STAT1 phosphorylation compared to IFN-β. (A) 
L929 cells were treated with either 1 ng/mL or 5 ng/mL IFN-β or the IFN-β FLETVR variant for either 
30 or 120 minutes. STAT1 phosphorylated at Y701, total STAT1 and actin were detected in whole cell 
lysates. This result is representative of triplicate independent experiments. (B) Densitometry of Western 
blots; data from the triplicate independent experiments are represented as intensity of phospho-STAT1 
relative to intensity of actin. Data expressed as mean + SD of triplicate independent experiments. 
Significance relative to untreated samples (UT), ** P < 0.01, **** P < 0.0001 (2-way ANOVA with 
Tukey’s multiple comparisons testing); significance relative to treatment with 1 ng/mL IFN-β for 30 
mins, # P < 0.05, ### P < 0.001, #### P < 0.0001 (2-way ANOVA with Tukey’s multiple comparisons 
testing). 
FIGURE 6. Quantitative RT-PCR analysis of the response of L929 cells to treatment with IFN-β ( ) 
or IFN-β FLETVR ( ) for 3 hours. The amplified target from each sample is relative to the levels of 
18S in the same sample. All data is normalized to mRNA levels detected in untreated cells ( ) and 
 at CA
RD
IFF U
N
IV
ERSITY
 on M
ay 30, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
18 
 
expressed as mean + SD of at least 3 independent experiments performed in technical triplicate. 
Significance indicated above data points compares treatment between IFN-β and IFN-β FLETVR at the 
same protein concentration (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P <0.0001 (2-way ANOVA 
with Sidak’s multiple comparisons testing)). All IFN-β treated samples (as demonstrated by the bracket 
at the right-hand side of each graph) show fold induction significantly greater than the untreated samples 
(## P < 0.01 or less; 2-way ANOVA with Dunnett’s multiple comparisons testing). Significant 
difference in fold induction between IFN-β FLETVR treated and untreated samples is indicated (## P 
< 0.01, # P < 0.05; 2-way ANOVA with Dunnett’s multiple comparisons testing)).  
FIGURE 7. Comparison of the biological responses of IFN-β and the IFN-β FLETVR variant on L929 
cells. (A) The specific anti-viral activities (IU mg-1) of IFN-β and IFN-β FLETVR is shown. Data shown 
are individual data points and mean + SD of independent experiments. **** P < 0.0001 (Student’s t-
test). (B) Comparison of the anti-proliferative activity of IFN-β and IFN-β FLETVR variant. Cell 
proliferation was monitored over 72h in the presence of the indicated doses of either IFN-β or IFN-β 
FLETVR. Data shown is the 72 hr time point and is expressed as mean + SD of triplicate independent 
experiments, performed in technical quadruplicate, analysed using 2-way ANOVA with Sidak’s 
multiple comparisons test, **** P < 0.0001.  
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